Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CYTOKINETICS, INCORPORATED

(CYTK)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 11/29 01:09:30 pm
39.7 USD   +1.72%
11/22INSIDER SELL : Cytokinetics
MT
11/15Cytokinetics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
AQ
11/15CYTOKINETICS INC : Other Events (form 8-K)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/22/2021 11/23/2021 11/24/2021 11/26/2021 11/29/2021 Date
40.9(c) 40.32(c) 40.9(c) 39.03(c) 39.59 Last
928 167 1 574 228 574 136 504 515 193 720 Volume
+0.10% -1.42% +1.44% -4.57% +1.43% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 21,1 M - -
Net income 2021 -252 M - -
Net cash position 2021 451 M - -
P/E ratio 2021 -11,8x
Yield 2021 -
Sales 2022 53,6 M - -
Net income 2022 -320 M - -
Net cash position 2022 189 M - -
P/E ratio 2022 -10,6x
Yield 2022 -
Capitalization 3 274 M 3 274 M -
EV / Sales 2021 134x
EV / Sales 2022 57,5x
Nbr of Employees 184
Free-Float 95,4%
More Financials
Company
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical... 
More about the company
Ratings of Cytokinetics, Incorporated
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about CYTOKINETICS, INCORPORATED
11/22INSIDER SELL : Cytokinetics
MT
11/15Cytokinetics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Confere..
AQ
11/15CYTOKINETICS INC : Other Events (form 8-K)
AQ
11/15Cytokinetics Announces Additional Results from GALACTIC-HF Presented at American Heart ..
AQ
11/15Cytokinetics, Incorporated Announces Additional Results from GALACTIC-HF Presented at A..
CI
11/12REFILE-UPDATE 4-Biden will nominate industry-friendly Califf to lead U.S. FDA
RE
11/08Cytokinetics Announces Two Presentations at the AHA Scientific Sessions 2021
AQ
11/08INSIDER SELL : Cytokinetics
MT
11/05CYTOKINETICS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
11/04HC Wainwright Adjusts Cytokinetics' Price Target to $62 from $58, Keeps Buy Rating
MT
11/03Cytokinetics Q3 Loss Widens As Revenue Drops
MT
11/03CYTOKINETICS : Q3 Earnings Snapshot
AQ
11/03Cytokinetics Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/03Earnings Flash (CYTK) CYTOKINETICS INCORPORATED Posts Q3 Revenue $5.4M, vs. Street Est ..
MT
11/03Cytokinetics Reports Third Quarter 2021 Financial Results
AQ
More news
News in other languages on CYTOKINETICS, INCORPORATED
11/08VENTE D'INITIÉS : Cytokinetics
11/03La perte de Cytokinetics au troisième trimestre s'accentue en raison de la baisse du ch..
11/03Earnings Flash (CYTK) CYTOKINETICS INCORPORATED affiche un chiffre d'affaires de 5,4 mi..
10/15VENTE D'INITIÉS : Cytokinetics
10/07Les actions du secteur de la santé terminent près du sommet du classement de jeudi
More news
Analyst Recommendations on CYTOKINETICS, INCORPORATED
More recommendations
Chart CYTOKINETICS, INCORPORATED
Duration : Period :
Cytokinetics, Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYTOKINETICS, INCORPORATED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 39,03 $
Average target price 52,90 $
Spread / Average Target 35,5%
EPS Revisions
Managers and Directors
Robert I. Blum President, Chief Executive Officer & Director
Ching W. Jaw Chief Financial Officer & Senior Vice President
Leonard Patrick Gage Chairman
Andrew A. Wolff Senior VP-Clinical Research & Development
Fady Ibraham Malik Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CYTOKINETICS, INCORPORATED87.82%3 274
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678